Endocrinology Vol. 140, No. 5 2125-2133
Copyright © 1999 by The Endocrine Society
Extracellular Matrix-Associated Bone Morphogenetic Proteins Are Essential for Differentiation of Murine Osteoblastic Cells in Vitro1
Miyuki Suzawa,
Yasuhiro Takeuchi,
Seiji Fukumoto,
Shigeaki Kato,
Naoto Ueno,
Kohei Miyazono,
Toshio Matsumoto and
Toshiro Fujita
Fourth Department of Internal Medicine (M.S., Y.T., S.F., T.F.),
University of Tokyo School of Medicine, Tokyo 112, Institute of
Molecular and Cellular Biology (M.S., S.K.), University of Tokyo, Tokyo
113, Japan; National Institute for Physiological Sciences (N.U.),
Okazaki, Cancer Institute Hospital (K.M.), First Department of Internal
Medicine (T.M.), University of Tokushima School of Medicine, Tokushima
770, Japan
Address all correspondence and requests for reprints to: Yasuhiro Takeuchi, M.D., Fourth Department of Internal Medicine, University of Tokyo School of Medicine, 328-6 Mejirodai, Bunkyo-ku, Tokyo 112-8688, Japan. E-mail: takeuchi-tky{at}umin.ac.jp
 |
Abstract
|
|---|
Osteoblastic differentiation is an essential part of bone formation
that compensates resorbed bone matrix to maintain its structural
integrity. Cells in an osteoblast lineage develop differentiated
phenotypes during a long-term culture in vitro. However,
intrinsic mechanisms whereby these cells differentiate into mature
osteoblasts are yet unclear. Bone morphogenetic proteins (BMPs)
stimulate osteoblastic differentiation and bone formation. We
demonstrate that mouse osteoblastic MC3T3-E1 cells constitutively
expressed messenger RNAs (mRNAs) for BMP-2 and BMP-4 and accumulated
BMPs in collagen-rich extracellular matrices. BMPs associated with the
extracellular matrices were involved in the induction of osteoblastic
differentiation of nonosteogenic mesenchymal cells as well as cells in
the osteoblast lineage. MC3T3-E1 cells constitutively expressed type IA
and type II BMP receptors. When a kinase-deficient type IA BMP receptor
was stably transfected to MC3T3-E1 cells to obliterate BMP-2/4
signaling, these cells not only failed to respond to exogenous BMP-2
but lost their capability of differentiation into osteoblasts that form
mineralized nodules. These observations strongly suggest that
endogenous BMP-2/4 accumulated in extracellular matrices are essential
for the osteoblastic differentiation of cells in the osteoblast
lineage. Therefore, the regulatory mechanism of BMP-2/4 actions in
osteoblastic cells is a principal issue to be elucidated for better
understanding of pathogenesis of bone losing diseases such as
osteoporosis.
 |
Introduction
|
|---|
OSTEOBLASTIC differentiation is an
essential part of bone formation, because active osteoblasts should be
recruited at the site of osteoclastic bone resorption to compensate the
continuous loss of bone matrix and maintain structural integrity of
skeletal system. Accumulating evidence indicates that several factors,
such as hormones, cytokines and growth factors, are involved in the
osteoblastic differentiation (1, 2). Among them, bone morphogenetic
proteins (BMPs)1 have been isolated from bone matrix as
factors inducing ectopic bone formation (3, 4). BMPs other than BMP-1
are members of TGF-ß superfamily, and BMP-2 and BMP-4 (BMP-2/4) are
supposed to be synthesized by osteoblastic cells in bone (5, 6). In
undifferentiated mesenchymal cells, a member of BMP family induces the
expression of cbfa1 gene that encodes the osteoblast
specific nuclear transcription factor essential for transcription of
bone matrix protein genes (7, 8, 9). BMPs stimulate the expression of
osteoblastic differentiation markers, such as alkaline phosphatase
(ALP) and osteocalcin (9, 10, 11). Although members of BMPs have also been
shown to be involved in the skeletal development (12, 13, 14) and in the
fracture healing process (15), their physiological significance in
osteoblastic differentiation and in bone formation during modeling and
remodeling of bone is yet uncertain.
Cells prepared from infantile or neonatal bone are able to
differentiate into mature osteoblasts that form bone-like nodules
in vitro in the presence of serum and ascorbic acid without
any other supplements (16, 17). This indicates that eutopic cells in
bone have intrinsic mechanisms that promote their differentiation into
osteoblasts for bone formation. However, it is yet uncertain what is
the mechanism for osteoblastic differentiation and how it works.
Impairment of the mechanism could contribute to the pathogenesis of
osteoporosis, a principal metabolic disease of losing bone mass, and
the way by which it is restored must be useful for the prevention and
improvement of bone loss.
The present study was undertaken to explore the mechanisms for
osteoblastic differentiation of cells in the osteoblast lineage using
nontransformed cell line MC3T3-E1 derived from neonatal mouse
calvariae. We present results indicating that endogenously synthesized
BMP-2/4 promote osteoblastic differentiation if the cells accumulate
collagenous extracellular matrices where BMP-2/4 are stored.
 |
Materials and Methods
|
|---|
Materials
Native BMPR-IA expression plasmid was a gift from Jeffry Wrana
(University of Toronto, Toronto, Canada). Monoclonal antibody (mAb)
against BMP-2/4 (h3b2/17.8.1) and recombinant human (rh) BMP-2 were
obtained from Genetics Institute (Cambridge, MA) and
Yamanouchi Pharmaceutical Co. (Tokyo), respectively. Mouse anti-FLAG M2
mAb and FITC-conjugated goat antimouse IgG polyclonal antibody were
purchased from Kodak (Eastman Kodak,
Rochester, NY) and Southern Biotechnology Associates
(Birmingham, AL), respectively.
Cloning of MC3T3-E1 cells constitutively expressing the
kinase-deficient BMP receptor-IA
Complementary DNA (cDNA) of kinase-deficient BMP receptor type
IA (BMPR-IA) (18) was subcloned into the expression plasmid pcDNA3
(Invitrogen, Carlsbad, CA). This plasmid contains a
3'-nested deletion clone of mouse BMPR-IA, and the cDNA codes for the
extracellular domain and transmembrane domain of the receptor. MC3T3-E1
cells were cultured in MEM supplement with 10% FBS in the presence and
absence of 50 mg/liter L-ascorbic acid. These cells were
transfected at 4060% confluence in 10-cm plastic dishes with pcDNA3
containing the kinase-deficient BMPR-IA or mock plasmid (pcDNA3 alone)
by calcium phosphate coprecipitation technique. Medium was freshly
changed after 16 h, and cells were maintained for further 48
h to reach confluence. Cells were, then dispersed and cultured in
MEM/10% FBS with G418 (300 µg/ml). Cells expressing mRNA for the
kinase-deficient BMPR-IA were cloned.
Alkaline phosphatase activity in osteoblastic cells
Cells were washed twice with ice-cold PBS and scraped in 10
mM Tris-HCl containing 2 mM MgCl2
and 0.05% Triton X-100, pH 8.2. The cell suspension was sonicated on
ice. Aliquots of supernatants were subjected to protein assay with a
kit from Bio-Rad Laboratories, Inc. (Hercules, CA),
according to Bradfords method and to ALP activity measurement. In
brief, the assay mixture contained 10 mM p-nitrophenyl
phosphate in 0.1 M sodium carbonate buffer, pH 10,
supplemented with 1 mM MgCl2, followed by an
incubation at 37 C for 30 min. After adding 0.1 M NaOH, the
amount of p-nitrophenol liberated was measured by spectrophotometer
(17).
RNA isolation and RT-PCR
Poly (A)+ RNA was isolated from cells that were
cultured with or without ascorbic acid for 3, 5, and 10 days using the
MicroFastTrack Kit (Invitrogen). For RT-PCR analysis, 100
ng poly (A)+ RNA was treated with DNase I (Gibco BRL, Grand Island, NY) and reverse transcribed using random
9-mer (TAKARA RNA PCR Kit ver.2, TAKARA Co., Ohtsu, Japan). The 5'- and
3'-primers used were as follows: BMP-2, 5'-GACGGACTGCGGTCTCCTAAAG-3'
and 5'-TCTGCAGATGTGAGAAACTCGTCA-3'; BMP-4, 5'-CGCCGTCATTCCGGATTACAT-3'
and 5'-GGCCCAATCTCCACTCCCTT-3'; BMPR-IA,
5'-TAGCACCAGAGGATACCTTGC-3' and 5'-AATGCTTCATCCTGT-TCCAAA-3';
BMPR-IB, 5'-TGCTCTTACGAAGCTCT GGA-3' and 5'-ATCTCTGTCCTTGAGAGGAG-3';
BMPR-II, 5'-CAGAATCAAGGA-ACGGC TATG-3' and
5'-TTGTTTACGGTCTCCTGTCA-3'. Expression of the kinase-deficient BMPR-IA
mRNA was detected by RT-PCR using T7 primer as a 5'-primer and
5'-TGGGAGTGGCACCTTCCA-3', which corresponds to a sequence in the pcDNA3
plasmid as a 3'-primer. PCR conditions are as follows; for BMP-2,
denature 94 C for 1 min, annealing 56 C for 1 min, extension 74 C for 1
min, this process was repeated 40 cycles followed by 74 C for 7 min;
for BMP-4, denature 94 C for 30 sec, annealing 58 C for 30 sec,
extension 74 C for 1 min, this process was repeated 40 cycles followed
by 74 C for 7 min; for BMPR-IA, -IB, and -II, denature 94 C for 30 sec,
annealing 58 C for 30 sec, extension 74 C for 1 min, this process was
repeated 35 cycles followed by 74 C for 7 min; for the kinase-deficient
BMPR-IA, denature 94 C for 1 min, annealing 58 C for 30 sec, extension
74 C for 30 sec, this process was repeated 35 cycles followed by 74 C
for 10 min. Then, PCR products were electrophoresed in 1.0% agarose
gel and visualized by ethidiumbromide staining. As a negative control,
we carried out PCR amplification without RT. No PCR products were
obtained in these experiments for all pairs of primers.
Examination of intracellular distribution of Smad1
Cells expressing mRNA for the kinase-deficient BMPR-IA were
transiently transfected with the expression plasmid of
FLAG-tagged-Smad1 (19) with or without cotransfection of
wild-type BMPR-IA using Cell Electroporator (BRL,
Gaithersburg, MD), and then incubated overnight at 37 C. Cells were
once dispersed by trypsinization, then plated on Lab-Tek chamber slides
(Nunc, Roskilde, Denmark) and allowed to adhere overnight.
Intracellular distribution of Smad1 was examined as described (19). In
brief, cells were washed and incubated for 1.5 h in the medium
with 0.2% FBS in the absence or presence of 400 ng/ml rhBMP-2 before
fixing. Cells on the slides were blocked in 10% goat serum for 1
h at room temperature and then incubated overnight at 4 C in 10% goat
serum containing anti-FLAG M2 mAb (20 µg/ml). After washing four
times, FITC-conjugated goat antimouse IgG polyclonal antibody
(1:200 dilution) in 10% goat serum was added and incubated for 1
h at room temperature followed by washing twice. Intracellular
distribution of FLAG-tagged Smad1 was microscopically examined.
Immunocytochemical analysis of BMP-2 and BMP-4
The cells were fixed with 4% paraformaldehyde in PBS for 5 min.
After washes three times with PBS, cells were immersed in methanol for
1 min. They were treated with 3% hydrogen peroxide for 5 min, and were
washed with PBS. Expression of BMP-2/4 was determined by a mouse mAb
(h3b2/17.8.1) against rhBMP-2 using a LSAB kit (DAKO Corp., Kyoto, Japan). This antibody reacts with both BMP-2 and
BMP-4. Cells were treated with a biotinylated secondary antibody
against mouse IgG, and incubated with horseradish peroxidase-conjugated
streptavidin. Immunoreactivity in cell layers was detected using AEC
substrate-chromogen system (DAKO Corp.).
The localization of BMP-2/4 was determined by an immunogold technique
with an electron microscopy using the same mAb. Cells on the six-well
culture dishes were fixed in 4% paraformaldehyde/0.5% glutaraldehyde
at 4 C for 30 min. Specimens were dehydrated with ethanol and embedded
in epoxy resin. Ultrathin sections were made with a diamond knife on
Ultracut N (Reichert-Nissei, Tokyo), and were examined with JEM-1200 EX
II transmission electron microscope (Nippon Denshi, Tokyo) following
the incubation with the primary antibody and the secondary antimouse
IgG gold antibody. In brief, the specimen were incubated in PBS/1% BSA
to saturate nonspecific binding sites. They were incubated for 1 h
in PBS/0.5% BSA containing the anti-BMP-2/4 mAb, and washed with PBS
followed by incubating with the antimouse IgG-gold antibody in
PBS/0.5% BSA for 1 h.
Mineralized nodules stained by von Kossas method
MC3T3-E1 cells expressing mRNA for the kinase-deficient BMPR-IA
or pcDNA3 alone were cultured for 3 weeks in the presence of ascorbic
acid and 5 mM ß- glycerophosphate. Mineralized nodules
were stained with silver nitrate according to von Kossas procedure as
described (17).
Preparation of detergent-resistant extracellular matrix layers of
osteoblastic cells
MC3T3-E1 cells were cultured on 6-well plastic dishes in the
presence of ascorbic acid for 10 days. Cells were solubilized with
0.5% sodium deoxycholate in 10 mM Tris-HCl, pH 8.0, at 4 C
for 10 min and washed twice with the same buffer. Solubilized materials
were extensively wiped away by several washes with ice-cold PBS (20).
Extracellular matrix (ECM) components resistant to the detergent
remained on dishes and were stored on ice in 1 ml PBS in the presence
and absence of 10 µg soluble form of BMPR-IA (21) for 1 h
followed by washing 3 times with PBS. Freshly dispersed cells were
inoculated on the coated dishes and cultured in MEM/10% FBS without
ascorbic acid at 37 C in 5% CO2 atmosphere. Cells were
subjected to ALP assay after 24 h.
Statistical analysis
Data were expressed as means ± SE. Statistical
significance was evaluated by ANOVA followed by post hoc method of
Bonferroni. Unadjusted P value less than 0.05 was considered
to be significant.
 |
Results
|
|---|
BMP-2 and BMP-4 expressed in osteoblastic cells are accumulated in
extracellular matrices
BMP-2/4 have been purified from bone matrix (3), potently
stimulate osteoblastic differentiation (10, 11), and induce ectopic
bone formation (4). To explore the mechanism whereby mouse MC3T3-E1
cells differentiate into mature osteoblastic cells during a long-term
culture, we first examined the expression of BMP-2/4 in these cells
through their differentiation process. MC3T3-E1 cells required ascorbic
acid to increase ALP activity as an osteoblastic differentiation marker
with culture periods of time (Fig. 1
).
They remained at the premature stage with low ALP activity in the
absence of ascorbic acid. Detection of transcripts for BMP-2 and BMP-4
by RT-PCR indicated that MC3T3-E1 cells constitutively expressed both
BMPs through the differentiation process (Fig. 1
, inset). To
confirm synthesis of BMPs by the cells, proteins of BMP-2/4 were
immunostained with a monoclonal antibody that specifically recognizes
both BMP-2 and BMP-4. Monolayer cells cultured in the presence and
absence of ascorbic acid, were diffusely stained with the anti-BMP
antibody (Fig. 2
, A and B).

View larger version (8K):
[in this window]
[in a new window]
|
Figure 1. Increase in alkaline phosphatase activity and
expressions of BMP-2 and BMP-4 in osteoblastic MC3T3-E1 cells with
culture periods of time. MC3T3-E1 cells were cultured in the presence
and absence of 50 mg/liter ascorbic acid for 10 days. Alkaline
phosphatase activities in cell layers were measured at the indicated
culture days. Transcripts of BMP-2 and BMP-4 were detected by RT-PCR
from poly (A)+ RNA extracted from cells at the indicated
culture days (inset).
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Figure 2. Immunostaining of osteoblastic MC3T3-E1 cell
layers with anti-BMP-2/4 mAb. MC3T3-E1 cells were cultured in the
absence (A) and presence (B, C) of 50 mg/liter ascorbic acid for 10
days. Monolayer of the cells (A, B) and detergent-resistant
extracellular matrix layers (C) were prepared as described in
Materials and Methods. BMP-2/4 expression was diffusely
detected using a mouse mAb (h3b2/17.8.1) against rhBMP-2.
Immunoreactivity was detected using LSAB kit. Control IgG gave no
positive reaction.
|
|
An accumulation of collagen-rich ECM by MC3T3-E1 cells depends upon the
presence of ascorbic acid in culture media (20, 22).
Detergent-resistant ECM layers laid down by cells in the presence of
ascorbic acid retained molecules immunoreactive with the BMP antibody
(Fig. 2C
). Much less ECM layers were accumulated in the absence of
ascorbic acid, and they did not present significant BMP
immunoreactivity (data not shown). By an electron microscopic
examination, BMP immunoreactivity was distributed along fibrous
structures around cells cultured with ascorbic acid, but was not
present in a pericellular space in the absence of ascorbic acid (Fig. 3
). These results indicate that MC3T3-E1
cells constitutively express BMP-2 and BMP-4, and that these BMP
proteins are stored in the ECM produced by the cells.

View larger version (28K):
[in this window]
[in a new window]
|
Figure 3. Electron micrographs from MC3T3-E1 cell layers
following immunolabeling with anti-BMP-2/4 mAb. MC3T3-E1 cells were
cultured in the absence (A) and presence (B, C) of 50 mg/liter ascorbic
acid for 10 days. Cell layers were prepared and examined as described
in Materials and Methods. Immunoreactivity for BMP-2/4
identified as dots of gold particles was distributed along fibrous
structures in the ECM around cells cultured with ascorbic acid (B), but
was not present in a pericellular space in the absence of ascorbic acid
(A). Control IgG gave no positive reaction (C).
|
|
Stimulation of osteoblastic differentiation by ECM-associated
BMP
Detergent-resistant ECM layers deposited by differentiated
osteoblastic cells stimulate ALP activity in less differentiated cells
(20, 23). To clarify if ECM-associated BMPs are responsible for the
stimulation of ALP activity, freshly dispersed MC3T3-E1 cells were
cultured for 24 h in the absence of ascorbic acid on the ECM
layers prepared from cells of high ALP activity. Preincubation of ECM
layers with soluble form of BMPR-IA that captures BMP-4 to neutralize
its actions (21), inhibited the elevation of ALP activity on the ECM to
a similar level to that in cells on plain plastic dishes (Table 1
). Treatment with soluble BMPR-IA
suppressed ALP activity in cells on plastic dishes in the presence of
ascorbic acid to abrogate the effect of ascorbic acid (0.56 ±
0.06 vs. 0.38 ± 0.01 nmol/min·µg-protein in the
absence and presence of soluble BMPR-IA, respectively,
P < 0.01, n = 3), and only slightly lowered that
in the absence of ascorbic acid (Table 1
). Conditioned media from
MC3T3-E1 cells at 10 days of culture in the presence and absence of
ascorbic acid did not stimulate ALP activity (data not shown). These
observations suggest that ECM-associated BMPs were responsible for the
stimulation of ALP activity in MC3T3-E1 cells. Although several other
growth factors than BMPs were possibly accumulated in the ECM, such
growth factors, for example TGF-ß1 (20), activin, insulin-like growth
factor I (IGF-I), epidermal growth factor, basic fibroblast
growth factor, failed to stimulate ALP activity in MC3T3-E1 cells (data
not shown).
View this table:
[in this window]
[in a new window]
|
Table 1. BMPs associated with ECM produced by MC3T3-E1 cells
stimulate ALP activity in MC3T3-E1 cells and non-osteogenic cells
|
|
BMPs are able to induce pluripotent mesenchymal cells to express
osteoblastic phenotypes. To clarify whether the ECM containing BMPs
stimulates to induce high ALP activity in nonosteoblastic mesenchymal
cells, we examined clonal mouse embryonic fibroblasts C3H10T1/2 and
bone marrow cells from long bones of mice. These cells were cultivated
in the absence of ascorbic acid on the ECM as described above for
24 h. ALP activity in all cells significantly increased when they
were seeded and maintained on the ECM, and this effect was abrogated
when the ECM layers were treated with soluble BMPR-IA before an
inoculation of cells (Table 1
). Thus, the ECM containing BMPs could
induce the differentiation not only of cells in the osteoblast lineage
but of pluripotent mesenchymal cells into osteoblasts.
Expression of kinase-deficient BMP receptor type IA eradicates
response of osteoblastic cells to BMP-2
There are two forms of receptors for BMP-2/4. Those are
hetero-oligomers of BMPR-II with either BMPR-IA or BMPR-IB
serine/threonine kinases (23). According to RT-PCR method, MC3T3-E1
cells constitutively expressed both BMPR-IA and BMPR-II receptors at
any differentiation stages in the presence and absence of ascorbic acid
(Fig. 4
). BMPR-IB was not detected in the
cells. Treatment of these cells with rhBMP-2 significantly stimulated
ALP activity in a dose-dependent fashion when cultured in the presence
of ascorbic acid (Fig. 5A
) and in the
absence of ascorbic acid to a less extent (data not shown).

View larger version (0K):
[in this window]
[in a new window]
|
Figure 4. Expression of receptors for BMP-2/4 in MC3T3-E1
cells. MC3T3-E1 cells were cultured in the presence and absence of 50
mg/liter ascorbic acid for 10 days. Transcripts of type IA, IB and II
receptors for BMP-2/4 were detected by RT-PCR from poly
(A)+ RNA extracted from cells at the indicated culture
days.
|
|

View larger version (8K):
[in this window]
[in a new window]
|
Figure 5. Effects of rhBMP-2 on alkaline phosphatase
activity in MC3T3-E1 cells expressing the kinase-deficient BMPR-IA. A,
MC3T3-E1 cells that stably express the kinase-deficient BMPR-IA, DN
clone 1 and DN clone 2, were cloned in the presence of G418. DN clone
cells, and control cells expressing pcDNA3 alone were cultured in the
presence of 50 mg/liter ascorbic acid for 4 days. Cells were treated
with various concentrations of rhBMP-2 for 3 days, and alkaline
phosphatase activities in cell layers were measured.
Inset, Results for DN clones are shown with an expanded
scale. Data are means ± SE of four determinants. *,
Significantly higher than the value obtained from the same clones
without rhBMP-2 (P < 0.01). **, Significantly less
than the control cultures without rhBMP-2 (P <
0.01). B, Expression of the kinase-deficient BMPR-IA mRNA was detected
by RT-PCR using T7 primer as a 5'-primer and a 3'-primer in pcDNA3
expression plasmid. Transcripts containing the kinase-deficient BMPR-IA
(closed arrowhead) were detected as a band of expected
size (933 bp) by RT-PCR from poly (A)+ RNA extracted from
DN clone 1 and DN clone 2 cells. A smaller fragment (257 bp) of pcDNA3
without insertions amplified by RT-PCR (open arrowhead)
was detected in the control cells. C, Expression of osteocalcin mRNA
was detected by Northern blot analysis. DN clone cells, and control
cells expressing pcDNA3 alone were cultured in the presence of 50
mg/liter ascorbic acid for 4 days. Cells were treated with various
concentrations of rhBMP-2 for 3 days, and total RNAs isolated from cell
layers were subjected to Northern blot analyzes. Twenty micrograms of
total RNA was loaded on each lane. The expression of GAPDH mRNA was
shown as an internal reference.
|
|
To clarify if BMP signaling is indispensable for osteoblastic
differentiation of MC3T3-E1 cells, we cloned the cells that stably
expressed kinase-negative BMPR-IA (
BMPR-IA) to obliterate BMP-2/4
signals. When expressed in Xenopus oocytes, this
BMPR-IA
blocks BMP signaling as a dominant negative (DN) receptor (18).
Mock-transfected cells were selected in the presence of G418 as
controls. Seven independent clones expressing
BMPR-IA mRNA (DN
clones) normally attached, spreaded and proliferated on culture dishes.
Because characteristics of all clones examined were essentially the
same in terms of their responsiveness to BMP-2 and changes in ALP
activity with time, results obtained from representative clones (DN
clones 1 and 2) were presented. To confirm the expression of
BMPR-IA
mRNA, transcribed pcDNA3 fragment containing
BMPR-IA sequence in DN
clones 1 and 2 was amplified by a RT-PCR method (Fig. 5B
). In control
cells, PCR product corresponding to pcDNA3 vector was obtained. In
contrast, longer PCR product containing
BMPR-IA insert was observed
in DN clones. After binding to the receptor, BMP-2/4 activate a
signaling molecule Smad1 that is translocated from cytoplasm to nucleus
upon its phosphorylation by the receptor serine/threonine kinase (19).
We examined the nuclear translocation of FLAG-tagged Smad1 transiently
expressed in DN clone cells. Transfected Smad1 diffusely distributed in
cytoplasmic compartments in DN clone cells either in the presence or
absence of rhBMP-2 (Fig. 6
, A and C).
Nuclear translocation of Smad1 upon the stimulation with 400 ng/ml
rhBMP-2 was only observed in DN cells overexpressing wild-type BMPR-IA
expression plasmid (Fig. 6
, B and D). These results indicate that DN
clones are refractory to BMP-2 at their receptor level, and that this
refractoriness can be restored by overexpressing the wild-type
BMPR-IA.

View larger version (18K):
[in this window]
[in a new window]
|
Figure 6. Nuclear translocation of Smad1 upon
stimulation with BMP-2 in MC3T3-E1 cells expressing the
kinase-deficient BMPR-IA. MC3T3-E1 cells that stably express the
kinase-deficient BMPR-IA, DN clone 1, were established in the presence
of G418. Cells were transiently transfected with the expression plasmid
of FLAG-tagged-Smad1 with (B, D) or without (A, C) that
of native BMPR-IA using Cell Electroporator (BRL) to DN clone 1, and
then incubated overnight at 37 C. Cells were once dispersed, then
plated on Lab-Tek chamber slides. Distribution of
FLAG-tagged-Smad1 was examined as described in
Materials and Methods. Cells were incubated for 1.5
h in the medium with 0.2% FBS in the absence (A, B) or presence (C, D)
of 400 ng/ml rhBMP-2 before fixing. Intracellular distribution of
FLAG-tagged-Smad1 was microscopically examined using
FITC-conjugated goat antimouse IgG polyclonal antibody. Nuclear
translocation of Smad1 from cytoplasmic compartment was
indicated by arrowheads (D).
|
|
Response of DN clones to rhBMP-2 to stimulate ALP activity was markedly
blunted in comparison with control cells (Fig. 5A
). The effect of
rhBMP-2 was only slight but dose dependent up to 400 ng/ml in DN
clones, although it was saturated at 200300 ng/ml in control cells.
In addition, ALP activity without rhBMP-2 was significantly lower in DN
clones than the control (Fig. 5A
). The effect of rhBMP-2 on the
expression of mRNA for osteocalcin, a late osteoblastic differentiation
marker, in DN clones was also negligible, and its basal level was less
in DN clones than that in control cells (Fig. 5C
). Thus, DN clones were
unresponsive to the stimulatory effect of BMP-2 on the osteoblastic
differentiation by the expression of
BMPR-IA.
Signaling from BMP receptors are required for osteoblastic
differentiation
Increasing ALP activity during the long-term culture in the
presence of ascorbic acid was observed in control MC3T3-E1 cells but
not in DN clones (Fig. 7A
). ALP
activities in DN clones after 10 days of culture were similar to those
in control cells in the absence of ascorbic acid. Cultures for 3 weeks
in the presence of ascorbic acid and 5 mM ß-
glycerophosphate induced to form mineralized nodules in the control
cells, but there were no nodules in cultures of DN clones (Fig. 7B
).
mRNA expression of BMP-2 and BMP-4 was observed both in DN clones and
in control cells (Fig. 7C
). These observations indicate that BMPR-IA
and its downstream signals are essentially required for differentiation
of osteoblastic cells.

View larger version (9K):
[in this window]
[in a new window]
|
Figure 7. Failure of development of osteoblastic
phenotypes in MC3T3-E1 cells expressing the kinase-deficient BMPR-IA.
A, MC3T3-E1 cells that stably express the kinase-deficient BMPR-IA, DN
clone 1 (closed squares) and DN clone 2 (open
squares), were cloned in the presence of G418. DN clone cells
and control cells expressing pcDNA3 alone (open circles)
were cultured in the presence of 50 mg/liter ascorbic acid for 10 days.
Control cells were also cultured in the absence of ascorbic acid for 10
days (closed circle). Alkaline phosphatase activities in
cell layers were measured at the indicated culture days. Data are
means ± SE of four determinants. B, Cells were
cultured for 3 weeks in the presence of 50 mg/liter ascorbic acid and 5
mM ß- glycerophosphate. Mineralized nodules were stained
with silver nitrate according to von Kossas procedure. C, Transcripts
of BMP-2 and BMP-4 were detected as bands of expected sizes (479 bp and
574 bp, respectively) by RT-PCR from poly (A)+ RNA
extracted from the control (lanes 1 and 4), DN clone 1 (lanes 2 and 5)
and DN clone 2 cells (lanes 3 and 6) cultured for 10 days.
|
|
Stimulation of osteoblastic differentiation on ECM layers of DN
clone cells
To test whether the ECM layers of DN clones are capable of
promoting osteoblastic differentiation, the control and DN clones of
MC3T3-E1 cells were cultured for 24 h in the absence of ascorbic
acid on ECM layers deposited by the control and DN clone cells. ALP
activity did not increase in DN clones on the ECM layers laid down by
control MC3T3-E1 cells cultured for 10 days in the presence of ascorbic
acid, but did increase in control cells (Table 2
). ECM layers of DN clones stimulated
ALP activity in control cells (Table 2
) but not in DN clone cells (data
not shown), indicating that ECM layers of DN clones were potent enough
to promote osteoblastic differentiation. Results shown here confirm
that DN clones fail to express osteoblastic phenotypes not due to less
competent extracellular milieu or lack of expression of BMP-2/4 but due
to inert receptors for BMP-2/4.
View this table:
[in this window]
[in a new window]
|
Table 2. ECM layers deposited by DN clones of MC3T3-E1 cells
expressing dominant-negative BMP receptor type IA stimulate ALP
activity in the control MC3T3-E1 cells
|
|
 |
Discussion
|
|---|
Factors and mechanisms that initiate and promote osteoblastic
differentiation physiologically have long been pursued. Cells in an
osteoblast lineage derived from bone, periosteum and bone marrow, have
a potency to differentiate into mature osteoblasts after a long-term
culture. Although treatment of these cells with members of BMP family,
such as BMP-2 and 4, are able to stimulate the differentiation process
(10, 11, 24) and these cells synthesize some BMPs (6), it is uncertain
what mechanisms intrinsically initiate and support the osteoblastic
differentiation. MC3T3-E1 cell line derived from neonatal mouse
calvaria is a good model to explore this issue, because these cells
spontaneously differentiate into mature osteoblasts with time in the
presence of serum and ascorbic acid (17, 22, 25). We have reported that
the expression of osteoblastic phenotypes in premature cells is
enhanced, when they are cultured on ECM layers laid down by
differentiated osteoblastic cells (20). The stimulatory factor(s)
accumulated in ECM layers of MC3T3-E1 cells are BMP-2/4 at least in
part, because these cells synthesized and accumulated BMP-2/4 in their
ECM layers (Figs. 2
and 3
), and because soluble BMPR-IA completely
blocked the stimulatory effect of the ECM (Table 1
). Furthermore, high
ALP activity was induced in nonosteoblastic mesenchymal cells, when
they were maintained on the ECM. Thus, one can assume that the ECM
containing BMPs is effective to induce osteoblastic differentiation. We
did not exclude possibility that other members of BMP family, such as
BMP-6, BMP-7 and GDF-5, known to stimulate osteoblastic
differentiation, might also be accumulated in the ECM of MC3T3-E1
cells, and that they were involved in the stimulatory effect.
There are several possibilities that explain the reason why the ECM
containing BMPs is competent enough for the differentiation. The first
is that the detergent-resistant ECM contains several growth factors,
such as TGF-ßs and IGFs (26). Growth factors other than BMPs are also
involved in the bone formation. TGF-ß is synthesized by osteoblastic
cells (27) and is accumulated in bone matrix, and so is IGF-I (28).
TGF-ß strongly stimulates the synthesis and the accumulation of bone
matrix proteins by osteoblasts (5, 29). IGF-I enhances the
proliferation of cells in the osteoblast lineage (30). Both of them
stimulate bone formation (31, 32), and decreases in these factors in
bone matrices are proposed to be associated with loss of bone mass.
TGF-ß content in bone is less in ovariectomized rats (33). It is also
reported that TGF-ß and IGF-I accumulated in human bone matrices
decrease with advancing age (34). However, no growth factors but BMPs
are able to promote osteoblastic differentiation of nonosteogenic
cells. TGF-ß has been shown to suppress the expression of
osteoblastic phenotypes and the formation of mineralized nodules in
osteoblastic cell cultures (16). Thus, BMPs could be principal factors
in the ECM of MC3T3-E1 cells that direct cells in the osteoblast
lineage toward mature osteoblasts, and TGF-ß and IGFs may exert their
effects on bone formation in a different way from BMPs.
The second one is that ECM proteins, such as collagen and fibronectin,
are also involved in the stimulation of osteoblastic differentiation.
We have reported that an interaction between type I collagen and
2ß1 integrin on osteoblastic cells is required for the promotion
of their differentiation (20). Their interaction activates focal
adhesion kinase (FAK) followed by an activation of its downstream
pathways including MAP kinase, and this FAK-MAP kinase cascade is
involved in the differentiation process (35). Because rhBMP-2 do not
directly enhance the activation of FAK or MAP kinase (unpublished
observations), and because endogenous BMPs are shown to be involved in
the differentiation, it is suggested that BMP signals stimulate
osteoblastic differentiation in conjunction with the integrin-FAK-MAP
kinase pathway activated by ECM proteins. Indeed, it is reported that
Ras, Raf, and AP-1, which are closely associated with the
integrin-FAK-MAP kinase pathway, are involved in BMP-4 signaling during
Xenopus embryonic development (36). The third possibility is
that immobilized BMPs in the ECM may be protected from proteolytic
degradation and ready to access to their receptors on the cell-surface
when cells attach to ECM components. Taken together, results in the
present study suggest that BMP-2/4 accumulated in ECM layers are highly
competent to stimulate osteoblastic differentiation. Thus, endogenous
BMPs are particularly important for the development of osteoblastic
phenotypes if they are accumulated in ECM layers. Although BMPs have
been reported to be bound to type IV collagen and other matrix
components (37), the mechanism whereby they were accumulated in the ECM
of osteoblastic MC3T3-E1 cells remains to be elucidated.
There has been no direct evidence indicating that BMPs initiate and
support osteoblastic differentiation during modeling and remodeling
process of bone. To clarify if BMPs are indispensable for the
differentiation of osteoblasts, we cloned MC3T3-E1 cells stably
expressing a dominant negative receptor for BMP-2/4 (
BMPR-IA) (18).
Although there is another type I receptor for BMP-2/4, BMPR-IB,
MC3T3-E1 cells express only BMPR-IA. Thus,
BMPR-IA is able to
eradicate effects of BMP-2/4 in these cells.
BMPR-IA expressing
cells (DN clones) we selected were refractory to BMP-2 at the step
before the nuclear translocation of Smad1, an immediate signal
transducer of BMPR-I, and failed to express osteoblastic phenotypes
with culture periods of time. Because expressions of BMP-2/4 were
observed in DN clones and the capability of their ECM layers to
stimulate ALP activity in control cells were not less than that of
control cells, signals generated by BMPR-IA were essentially required
for the spontaneous osteoblastic differentiation of MC3T3-E1 cells.
MC3T3-E1 cells do not differentiate in the absence of ascorbic acid
because matrix type I collagen does not sufficiently accumulate in
extracellular spaces (20, 22). BMP-2/4 and their receptors were all
expressed in these cells even in the absence of ascorbic acid. This and
results described above suggest that endogenous BMP-2/4 exert their
effect if cells accumulate collagen-rich ECM layers. This hypothesis is
further corroborated by the fact that ALP activity in control cells
increased even in the absence of ascorbic acid on either ECM layer
deposited by DN clones or control MC3T3-E1 cells. Therefore, both
appropriate ECM layers and BMP actions are required for the
osteoblastic differentiation.
A previous report showing that BMP-4 is transiently but highly
expressed at fracture sites during the healing process (15) supports
our notion that endogenous BMPs are important for the osteoblastic
differentiation that promotes bone formation. In another aspect of
pathophysiology, augmented BMP actions might be involved in the
pathogenesis of some diseases. It is suggested that the expression of
BMP receptors is involved in the development of ossification of
paravertebral ligaments (38). Osteosarcoma cells sometimes strongly
express members of BMP family (39), which may constitutively activate
the signals out of physiological regulations and may be involved in
their oncogenesis. Results presented here demonstrate that the
regulatory mechanism of BMP-2/4 actions in osteoblastic cells as well
as that of the ECM production is one of principal issues to be
elucidated in the control of bone formation for better understanding of
pathogenesis of osteoporosis and for development of its therapeutic
procedures.
 |
Acknowledgments
|
|---|
We thank Tomoko Kikuchi for her technical assistance and are
grateful to Masaki Yanagishita for helpful discussions. We thank Jeffry
Wrana for providing us BMPR-IA expression plasmid and Yumiko Nagai for
microscopic examinations.
 |
Footnotes
|
|---|
1 This study was presented in part in the 19th Annual Meeting of the
American Society for Bone and Mineral Research, Cincinnati, Ohio,
September 1014, 1997. This work was supported in part by
Grants-in-Aid for Scientific Research from the Ministry of Education,
Science and Culture (to Y.T. and T.M.), Grants for Silver Science
Program on the Investigation of Osteoporosis from the Ministry of
Health and Welfare of Japan (to T.M.), and Grants from Research Society
for Metabolic Bone Diseases (to Y.T.). 
Received September 1, 1998.
 |
References
|
|---|
-
Stein GS, Lian JB 1993 Molecular mechanisms
mediating proliferation/differentiation interrelationships during
progressive development of the osteoblast phenotype. Endocr Rev 14:424442[CrossRef][Medline]
-
Reddi AH 1994 Bone and cartilage differentiation.
Curr Opin Gene Dev 4:737744[CrossRef][Medline]
-
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters
MJ, Kriz RW, Hewick RM, Wang EA 1988 Novel regulators of bone
formation: molecular clones and activities. Science 242:15281533[Abstract/Free Full Text]
-
Wang EA, Rosen V, DAlessandro JS, Baunduy M, Cordes
P, Harada T, Israel DI, Hewick RM, Kerns KM, LaPan P, Luxenberg DP,
McQuaid D, Moutsatsos IK, Nove J, Wozney JM 1990 Recombinant human
bone morphogenetic protein induces bone formation. Proc Natl Acad Sci
USA 87:22202224[Abstract/Free Full Text]
-
Centrella M, Horowitz MC, Wozney JM, McCarthy TL 1994 Transforming growth factor-ß gene family members and bone.
Endocr Rev 15:2739[CrossRef][Medline]
-
Harris SE, Sabatini M, Harris MA, Feng JQ, Wozney J,
Mundy GR 1994 Expression of bone morphogenetic protein messenger
RNA in prolonged cultures of fetal rat calvarial cells. J Bone
Miner Res 9:389394[Medline]
-
Banerjee C, Hiebert SW, Stein JL, Lian JB, Stein
GS 1996 An AML-1 consensus sequence binds an osteoblast-specific
complex and transcriptionally activates the osteocalcin gene. Proc Natl
Acad Sci USA 93:49684973[Abstract/Free Full Text]
-
Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K,
Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R,
Kitamura Y, Yoshiki S, Kishimoto T 1997 Targeted disruption of
Cbfa1 results in a complete lack of bone formation owing to
maturational arrest of osteoblasts. Cell 89:755764[CrossRef][Medline]
-
Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G 1997 Osf2/Cbfa1: a transcriptional activator of osteoblast
differentiation. Cell 89:747754[CrossRef][Medline]
-
Yamaguchi A, Katagiri T, Ikeda T, Wozney JM, Rosen V,
Wang EA, Kahn AJ, Suda T, Yoshiki S 1991 Recombinant human bone
morphogenetic protein-2 stimulates osteoblastic maturation and inhibits
myogenic differentiation in vitro. J Cell Biol 113:681687[Abstract/Free Full Text]
-
Yamaguchi A, Ishizuya T, Kintou N, Wada Y, Katagiri T,
Wozney JM, Rosen V, Yoshiki S 1996 Effects of BMP-2, BMP-4, and
BMP-6 on osteoblastic differentiation of bone marrow-derived stromal
cell lines, ST2 and MC3T3G2/PA6. Biochem Biophys Res Commun 220:366371[CrossRef][Medline]
-
Duprez DM, Kostakopoulou K, Francis-West PH, Tickle C,
Brickell PM 1996 Activation of Fgf-4 and HoxD gene expression by
BMP-2 expressing cells in the developing chick limb. Development 122:18211828[Abstract]
-
Hofmann C, Luo G, Balling R, Karsenty G 1996 Analysis of limb patterning in BMP-7-deficient mice. Dev Genet 19:4350[CrossRef][Medline]
-
Kawakami Y, Ishikawa T, Shimabara M, Tanda N,
Enomoto-Iwamoto M, Iwamoto M, Kuwana T, Ueki A, Noji S, Nohno T 1996 BMP signaling during bone pattern determination in the developing
limb. Development 122:35573566[Abstract]
-
Nakase T, Nomura S, Yoshikawa H, Hashimoto J, Hirota S,
Kitamura Y, Oikawa S, Ono K, Takaoka K 1994 Transient and
localized expression of bone morphogenetic protein 4 messenger RNA
during fracture healing. J Bone Miner Res 9:651659[Medline]
-
Breen EC, Ignotz RA, McCabe L, Stein JL, Stein GS, Lian
JB 1994 TGF-ß alters growth and differentiation related gene
expression in proliferating osteoblasts in vitro, preventing
development of the mature bone phenotype. J Cell Physiol 160:323335[CrossRef][Medline]
-
Matsumoto T, Igarashi C, Takeuchi Y, Harada S, Kikuchi
T, Yamato H, Ogata E 1991 Stimulation by 1,25-dihydroxyvitamin
D3 of in vitro mineralization induced by
osteoblast-like MC3T3E1 cells. Bone 12:2732[Medline]
-
Suzuki A, Thies RS, Yamaji N, Song JJ, Wozney JM,
Murakami K, Ueno N 1994 A truncated bone morphogenetic protein
receptor affects dorsal-ventral patterning in the early Xenopus embryo.
Proc Natl Acad Sci USA 91:1025510259[Abstract/Free Full Text]
-
Hoodless PA, Haerry T, Abdollah S, Stapleton M,
OConnor MB, Attisano L, Wrana JL 1996 MADR1, a MAD-related
protein that functions in BMP2 signaling pathways. Cell 85:489500[CrossRef][Medline]
-
Takeuchi Y, Nakayama K, Matsumoto T 1996 Differentiation and cell surface expression of transforming growth
factor-ß receptors are regulated by interaction with matrix collagen
in murine osteoblastic cells. J Biol Chem 271:39383944[Abstract/Free Full Text]
-
Natsume T, Tomita S, Iemura S, Kinto N, Yamaguchi A,
Ueno N 1997 Interaction between soluble type I receptor for bone
morphogenetic protein and bone morphogenetic protein-4. J Biol
Chem 271:1153511540
-
Franceschi RT, Iyer BS, Cui Y 1994 Effects of
ascorbic acid on collagen matrix formation and osteoblast
differentiation in murine MC3T3E1 cells. J Bone Miner Res 9:843854[Medline]
-
Shi S, Kirk M, Kahn AJ 1996 The role of type I
collagen in the regulation of the osteoblast phenotype. J Bone
Miner Res 11:11391145[Medline]
-
Gitelman SE, Kirk M, Ye JQ, Filvaroff EH, Kahn AJ,
Derynck R 1995 Vgr-1/BMP-6 induces osteoblastic differentiation of
pluripotential mesenchymal cells. Cell Growth Differ 6:827836[Abstract]
-
Quarles LD, Yohay DA, Lever LW, Caton R, Wenstrup
RJ 1992 Distinct proliferative and differentiated stages of murine
MC3T3E1 cells in culture: an in vitro model of osteoblast
development. J Bone Miner Res 7:683692[Medline]
-
Slater M, Patava J, Kingham K, Mason RS 1994 Modulation of growth factor incorporation into ECM of human
osteoblast-like cells in vitro by 17ß-estradiol. Am J
Physiol 267:E990E1001
-
Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P,
Reddi Reddi AH, Termine JD, Sporn MB, Roberts AB 1987 Osteoblasts
synthesize and respond to transforming growth factor-type ß (TGF-ß)
in vitro. J Cell Biol 105:457463[Abstract/Free Full Text]
-
Hauschka PV, Maurakos AE, Lafrati MD, Doleman SE,
Klagsbrun M 1986 Growth factors in bone matrix. J Biol Chem 261:1266512674[Abstract/Free Full Text]
-
Takeuchi Y, Matsumoto T, Ogata E, Shishiba Y 1993 Effects of transforming growth factor-ß1 and L-ascorbate on synthesis
and distribution of proteoglycans in murine osteoblast-like cells.
J Bone Miner Res 8:821827
-
Hock JM, Centrella M, Canalis E 1988 Insulin-like
growth factor I has independent effects on bone matrix formation and
cell replication. Endocrinology 122:254260[Abstract]
-
Hock JM, Canalis E, Centrella M 1990 Transforming
growth factor-ß stimulates bone matrix apposition and bone cell
replication in cultured fetal rat calvariae. Endocrinology 126:421426[Abstract]
-
Pfeilschifter J, Oechsner M, Naumann A, Gronwald RG,
Minne HW, Ziegler R 1990 Stimulation of bone matrix apposition
in vitro by local growth factors: a comparison between
insulin-like growth factor I, platelet-derived growth factor, and
transforming growth factor ß. Endocrinology 127:6975[Abstract]
-
Finkelman RD, Bell NH, Strong DD, Demers LM, Baylink
DJ 1992 Ovariectomy selectively reduces the concentration of
transforming growth factor ß in rat bone: implications for estrogen
deficiency-associated bone loss. Proc Natl Acad Sci USA 89:1219012193[Abstract/Free Full Text]
-
Nicolas V, Prewett A, Bettica P, Mohan S, Finkelman RD,
Baylink DJ, Farley JR 1994 Age-related decreases in insulin-like
growth factor-I and transforming growth factor-ß in femoral cortical
bone from both men and women: implications for bone loss with aging.
J Clin Endocrinol Metab 78:10111016[Abstract]
-
Takeuchi Y, Suzawa M, Kikuchi T, Nishida E, Fujita
T, Matsumoto T 1997 Differentiation and transforming growth
factor-ß receptor down-regulation by collagen-
2ß1 integrin
interaction is mediated by focal adhesion kinase and its downstream
signals in murine osteoblastic cells. J Biol Chem 272:2930929316[Abstract/Free Full Text]
-
Xu RH, Dong Z, Maeno M, Kim J, Suzuki A, Ueno N, Sredni
D, Colburn NH, Kung HF 1996 Involvement of Ras/Raf/AP-1 in BMP-4
signaling during Xenopus embryonic development. Proc Natl Acad Sci USA 93:834838[Abstract/Free Full Text]
-
Paralkar VM, Weeks BS, Yu YM, Kleinman HK, Reddi AH 1992 Recombinant human bone morphogenetic protein 2B stimulates PC12
cell differentiation: potentiation and binding to type IV collagen.
J Cell Biol 119:17211728[Abstract/Free Full Text]
-
Yonemori K, Imamura T, Ishidou Y, Okano T, Matsunaga S,
Yoshida H, Kato M, Sampath TK, Miyazono K, ten Dijke P, Sakou T 1997 Bone morphogenetic protein receptors and activin receptors are
highly expressed in ossified ligament tissues of patients with
ossification of the posterior longitudinal ligament. Am J Pathol 150:13351347[Abstract]
-
Yoshikawa H, Rettig WJ, Takaoka K, Alderman E, Rup B,
Rosen V, Wozney JM, Lane JM, Huvos AG, Garin CP 1994 Expression of
bone morphogenetic proteins in human osteosarcoma. Immunohistochemical
detection with monoclonal antibody. Cancer 73:8591[CrossRef][Medline]
This article has been cited by other articles:

|
 |

|
 |
 
J. A. Phillippi, E. Miller, L. Weiss, J. Huard, A. Waggoner, and P. Campbell
Microenvironments Engineered by Inkjet Bioprinting Spatially Direct Adult Stem Cells Toward Muscle- and Bone-Like Subpopulations
Stem Cells,
January 1, 2008;
26(1):
127 - 134.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. R. Bowers, J. W. Kim, T. C. Otto, and M. D. Lane
Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: Role of the BMP-4 gene
PNAS,
August 29, 2006;
103(35):
13022 - 13027.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Wang, C. C. Clark, and C. T. Brighton
Up-Regulation of Bone Morphogenetic Proteins in Cultured Murine Bone Cells with Use of Specific Electric Fields
J. Bone Joint Surg. Am.,
May 1, 2006;
88(5):
1053 - 1065.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Oshima, M. Abe, J. Asano, T. Hara, K. Kitazoe, E. Sekimoto, Y. Tanaka, H. Shibata, T. Hashimoto, S. Ozaki, et al.
Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2
Blood,
November 1, 2005;
106(9):
3160 - 3165.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Sevetson, S. Taylor, and Y. Pan
Cbfa1/RUNX2 Directs Specific Expression of the Sclerosteosis Gene (SOST)
J. Biol. Chem.,
April 2, 2004;
279(14):
13849 - 13858.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. F. Pera, J. Andrade, S. Houssami, B. Reubinoff, A. Trounson, E. G. Stanley, D. W.-v. Oostwaard, and C. Mummery
Regulation of human embryonic stem cell differentiation by BMP-2 and its antagonist noggin
J. Cell Sci.,
March 1, 2004;
117(7):
1269 - 1280.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Langenfeld and J. Langenfeld
Bone Morphogenetic Protein-2 Stimulates Angiogenesis in Developing Tumors
Mol. Cancer Res.,
March 1, 2004;
2(3):
141 - 149.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Majsterek, E. McAdams, E. Adachi, S. T. Dhume, and A. Fertala
Prospects and limitations of the rational engineering of fibrillar collagens
Protein Sci.,
September 1, 2003;
12(9):
2063 - 2072.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Minamide, S. D. Boden, M. Viggeswarapu, G. A. Hair, C. Oliver, and L. Titus
Mechanism of Bone Formation with Gene Transfer of the cDNA Encoding for the Intracellular Protein LMP-1
J. Bone Joint Surg. Am.,
May 28, 2003;
85(6):
1030 - 1039.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Canalis, A. N. Economides, and E. Gazzerro
Bone Morphogenetic Proteins, Their Antagonists, and the Skeleton
Endocr. Rev.,
April 1, 2003;
24(2):
218 - 235.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. C. D'Alonzo, A. J. Kowalski, D. T. Denhardt, G. A. Nickols, and N. C. Partridge
Regulation of Collagenase-3 and Osteocalcin Gene Expression by Collagen and Osteopontin in Differentiating MC3T3-E1 Cells
J. Biol. Chem.,
June 28, 2002;
277(27):
24788 - 24798.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. R. Beck Jr., B. Zerler, and E. Moran
Gene Array Analysis of Osteoblast Differentiation
Cell Growth Differ.,
February 1, 2001;
12(2):
61 - 83.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
H. C. Anderson, P. T. Hodges, X. M. Aguilera, L. Missana, and P. E. Moylan
Bone Morphogenetic Protein (BMP) Localization in Developing Human and Rat Growth Plate, Metaphysis, Epiphysis, and Articular Cartilage
J. Histochem. Cytochem.,
November 1, 2000;
48(11):
1493 - 1502.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
G. Xiao, D. Jiang, P. Thomas, M. D. Benson, K. Guan, G. Karsenty, and R. T. Franceschi
MAPK Pathways Activate and Phosphorylate the Osteoblast-specific Transcription Factor, Cbfa1
J. Biol. Chem.,
February 11, 2000;
275(6):
4453 - 4459.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Kimura, R. Matsuo, H. Shibuya, K. Nakashima, and T. Taga
BMP2-induced Apoptosis Is Mediated by Activation of the TAK1-p38 Kinase Pathway That Is Negatively Regulated by Smad6
J. Biol. Chem.,
June 2, 2000;
275(23):
17647 - 17652.
[Abstract]
[Full Text]
[PDF]
|
 |
|